share_log

Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant

Benzinga Real-time News ·  Jun 27, 2022 20:50
  • Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.
  • The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.
  • Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months. 
  • A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.
  • The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.
  • Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower. 
  • The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.
  • Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.
  • Image by x3 from Pixabay
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment